Sarcopenia is a condition characterized by the loss of skeletal muscle mass and function. Although it is primarily a disease of the elderly, its development may be associated with conditions not exclusively seen in the elderly. Low or gradual loss of muscle mass, general weakness, and decreased stamina are common symptoms of sarcopenia, which affects physical activity levels. Low levels of physical activity further contribute to muscle contraction.
The global sarcopenia treatment market generated $2.57 billion in 2020, and is anticipated to reach $4.70 billion by 2030, witnessing a CAGR of 6.1% from 2021 to 2030. In-depth information about opportunities, key drivers, restraints, and their impact analysis on the market is offered in the report.
Factors such as the increase in the geriatric population and the increase in initiatives undertaken by the government and private organizations drive the global sarcopenia treatment market. On the other hand, the lack of effective sarcopenia therapies on the market is expected to hamper growth. Conversely, increasing adoption of supplements and increasing malnutrition and vitamin deficiency in developing countries are the factors that should provide lucrative market opportunities.
Download Sample Report- https://www.alliedmarketresearch.com/request-sample/10891
- CAGR: 6.1%
- Current Market Size: USD 2.57 Billion
- Forecast Growing Region: APAC
- Largest Market: North America
- Projection Time: 2021 – 2030
- Base Year: 2021
Impact of Covid-19 on Sarcopenia Treatment Market-
- The COVID-19 pandemic is expected to have a positive impact on the sarcopenia treatment market.
- As patients with sarcopenia are more exposed to COVID-19 infection, the pandemic has caused many cases of sarcopenia, especially in the elderly population. • Lockdown and uncertainty in the food delivery chain has led to the unavailability of protein-rich foods and other nutritious foods. This has affected people’s overall health and has led to wasting muscle mass and other muscle ailments in people with other health conditions.
Based on treatment, the protein supplement segment is accounted for the largest market share in 2020, contributing to more than two-fifths of the total share. On the other hand, the vitamin D and calcium supplement segment is estimated to witness the fastest CAGR of 7.4% from 2021 to 2030.
Based on the distribution channel, the hospital pharmacies segment contributed to the largest share in 2020, accounting for more than half of the global sarcopenia treatment market, and is projected to dominate the market during the forecast period. However, the online pharmacies segment is expected to manifest the highest CAGR of 8.8% from 2021 to 2030.
Speak to our Analyst- https://www.alliedmarketresearch.com/connect-to-analyst/10891
Based on region, Asia-Pacific contributed to the highest share in 2020, followed by North America and Europe, holding nearly two-fifths of the total market share, and is expected to maintain the lead throughout the forecast period. The region is expected to manifest the fastest CAGR of 7.5% during the forecast period.
Leading players of the global sarcopenia treatment market analyzed in the research include
American Way (Amway) Corporation,
Sanofi, Inc.,
GlaxoSmithKline plc.
Nestle S.A.,
Bayer AG,
Pfizer, Inc.
Novartis AG,
Zydus Cadila, Ltd.,
F-Hoffmann La-Roche,
and Abbott laboratories, Inc.
Know more https://www.alliedmarketresearch.com/press-release/sarcopenia-treatment-market.html